← boardnext 2026-08
PHVS
Pharvaris Netherlands B.V.distress 3/10 · well-funded / low risk$33.87-1%today-6% from 52w high
Lead: Hereditary Angioedema (HAE)
Revenue
pre-revenue
Liquidity
$247M
Runway
1.8 yrs
Shares 1y
0%
Price & events
+21.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.4%
1D
+0.6%
1W
+2.0%
1M
+24.1%
3M
+21.1%
6M
+62.5%
1Y
+81.0%
2Y
+133.6%
5Y
+16.8%
All
Overview
- Market Cap
- $2.21B
- Volume
- 18.76K
- 52 Week Range
- $19.61 – $35.96
- Total Shares
- 65.21M
- Float Shares
- 39.67M
- Short %
- 1.71%
- % Held by Insiders
- 6.14%
- % Held by Institutions
- 85.30%
- RVOL
- 0.04x
- Beta
- -2.34
Pipeline stages · 1 programs
Deucrictibant
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 4 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08 Estimated 50% readout ~2026-10-15 | Phase 3 | Deucrictibant | Hereditary Angioedema (HAE) | — | active not recruiting |
| 2027-06 Estimated 50% readout ~2027-08-15 | Phase 2/3 | deucrictibant | Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, Hereditary Angioedema - Type 3, C1 Esterase Inhibitor [C1-INH] Deficiency, C1 Esterase Inhibitor Deficiency, C1 Esterase Inhibitor, Deficiency of, C1 Inhibitor Deficiency, Hereditary Angioedema Type III, Hereditary Angioedema (HAE), Hereditary Angioedema Type I and II, HAE With Normal C1 Esterase Inhibitor | — | enrolling by invitation |
| 2027-06 Estimated 50% readout ~2027-08-15 | Phase 3 | Deucrictibant | Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH) | — | recruiting |
| 2028-12 Estimated 50% readout ~2029-02-14 | Phase 3 | Deucrictibant | Hereditary Angioedema (HAE) | — | recruiting |
Catalyst news & presentations · 1
- 2026-08-12Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $47 (+39% upside) · 14 analysts
- 2026-07-15Wells FargoOverweight
- 2026-06-25Morgan StanleyOverweight
- 2026-05-13CitizensMarket Outperform
- 2026-04-09Wolfe ResearchOutperform
- 2026-04-07WedbushOutperform
- 2026-04-06RBC CapitalOutperform
Competitors — Hereditary Angioedema (HAE)
- none identified
Recent news
- 2026-07-22Pharvaris publishes review on bradykinin B2 receptor research - Investing.com
- 2026-07-20Here's why Pharvaris NV (PHVS) is a great momentum stock to buy - MSN
- 2026-07-20(PHVS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
- 2026-07-17Morgan Stanley Maintains Pharvaris N.V. (PHVS) Overweight Recommendation - MSN
- 2026-07-15Here's Why Pharvaris N.V. (PHVS) is a Great Momentum Stock to Buy - Yahoo Finance
- 2026-07-15Wells Fargo initiates Pharvaris stock with Overweight rating - Investing.com
- 2026-07-14Pharvaris (PHVS) CMO Lu Peng reports 226-share tax withholding event - Stock Titan
- 2026-07-14Wall Street Analysts Believe Pharvaris (PHVS) Could Rally 36.16%: Here's is How to Trade - Zacks Investment Research
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.